Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Karl-Johan Malmberg

Showing results (101-110 of 127) with videos related to

Pageof 13
Sort By:
Biorxiv : the Preprint Server for Biology|October 24, 2023
Genetic ablation of adhesion ligands averts rejection of allogeneic immune cellsQuirin Hammer, Karlo Perica, Hanna van Ooijen, et al.
Blood Advances|December 5, 2023
Systematic evaluation of donor-KIR/recipient-HLA interactions in HLA-matched hematopoietic cell transplantation for AMLJoshua A Fein, Roni Shouval, Elizabeth Krieger, et al.
Cell Stem Cell|July 9, 2024
Genetic ablation of adhesion ligands mitigates rejection of allogeneic cellular immunotherapiesQuirin Hammer, Karlo Perica, Rina M Mbofung, et al.
Cell Reports|April 28, 2016
Critical Role of CD2 Co-stimulation in Adaptive Natural Killer Cell Responses Revealed in NKG2C-Deficient HumansLisa L Liu, Johannes Landskron, Eivind H Ask, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 16, 2018
Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AMLAndreas T Björklund, Mattias Carlsten, Ebba Sohlberg, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 14, 2023
Functional SARS-CoV-2 cross-reactive CD4<sup>+</sup> T cells established in early childhood decline with ageMarion Humbert, Anna Olofsson, David Wullimann, et al.
Neuro-Oncology|July 11, 2026
iPSC-derived NK cell therapy induces durable responses in glioblastoma and overcomes resistance via a B7-H3-targeted tri-specific killer engagerJian-Fang Ning, Zachary B Davis, Qudsia Zeb, et al.
Cytotherapy|December 9, 2025
Expanded adaptive NKG2C+ NK cells exhibit potent ADCC and functional responses against HBV-infected hepatoma cell linesJonida Kokiçi, Helena Arellano-Ballestero, Benjamin Hammond, et al.
Biorxiv : the Preprint Server for Biology|June 12, 2025
Expanded adaptive NKG2C+ NK cells exhibit potent ADCC and functional responses against HBV-infected hepatoma cell linesJonida Kokiçi, Helena Arellano-Ballestero, Benjamin Hammond, et al.
Nature Communications|November 29, 2022
Quadruple gene-engineered natural killer cells enable multi-antigen targeting for durable antitumor activity against multiple myelomaFrank Cichocki, Ryan Bjordahl, Jodie P Goodridge, et al.
Pageof 13

Showing results (101-110 of 127) with videos related to

Sort By:
Pageof 13
Biorxiv : the Preprint Server for Biology|October 24, 2023
Genetic ablation of adhesion ligands averts rejection of allogeneic immune cellsQuirin Hammer, Karlo Perica, Hanna van Ooijen, et al.
Blood Advances|December 5, 2023
Systematic evaluation of donor-KIR/recipient-HLA interactions in HLA-matched hematopoietic cell transplantation for AMLJoshua A Fein, Roni Shouval, Elizabeth Krieger, et al.
Cell Stem Cell|July 9, 2024
Genetic ablation of adhesion ligands mitigates rejection of allogeneic cellular immunotherapiesQuirin Hammer, Karlo Perica, Rina M Mbofung, et al.
Cell Reports|April 28, 2016
Critical Role of CD2 Co-stimulation in Adaptive Natural Killer Cell Responses Revealed in NKG2C-Deficient HumansLisa L Liu, Johannes Landskron, Eivind H Ask, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 16, 2018
Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AMLAndreas T Björklund, Mattias Carlsten, Ebba Sohlberg, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 14, 2023
Functional SARS-CoV-2 cross-reactive CD4<sup>+</sup> T cells established in early childhood decline with ageMarion Humbert, Anna Olofsson, David Wullimann, et al.
Neuro-Oncology|July 11, 2026
iPSC-derived NK cell therapy induces durable responses in glioblastoma and overcomes resistance via a B7-H3-targeted tri-specific killer engagerJian-Fang Ning, Zachary B Davis, Qudsia Zeb, et al.
Cytotherapy|December 9, 2025
Expanded adaptive NKG2C+ NK cells exhibit potent ADCC and functional responses against HBV-infected hepatoma cell linesJonida Kokiçi, Helena Arellano-Ballestero, Benjamin Hammond, et al.
Biorxiv : the Preprint Server for Biology|June 12, 2025
Expanded adaptive NKG2C+ NK cells exhibit potent ADCC and functional responses against HBV-infected hepatoma cell linesJonida Kokiçi, Helena Arellano-Ballestero, Benjamin Hammond, et al.
Nature Communications|November 29, 2022
Quadruple gene-engineered natural killer cells enable multi-antigen targeting for durable antitumor activity against multiple myelomaFrank Cichocki, Ryan Bjordahl, Jodie P Goodridge, et al.
Pageof 13